OCA, an FXR agonist derived from chenodeoxycholic acid, has shown promise in the treatment of non-alcoholic steatohepatitis (MASH) and has improved the histological characteristics of MASH, particularly with regard to the NAFLD Activity Score (NAS) [229,230]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.